March 7, 2022
(press release)
–
Drug maker,
However, the company said it "intends to continue working with FDA to evaluate the regulatory pathway for the pediatric use of COVAXIN." Earlier,
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.